These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29809239)

  • 1. Botulinum toxin for hereditary spastic paraplegia: effects on motor and non-motor manifestations.
    Servelhere KR; Faber I; Martinez A; Nickel R; Moro A; Germiniani FMB; Moscovich M; Blume TR; Munhoz RP; Teive HAG; França MC
    Arq Neuropsiquiatr; 2018 Mar; 76(3):183-188. PubMed ID: 29809239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional effects of botulinum toxin type-A treatment and subsequent stretching of spastic calf muscles: a study in patients with hereditary spastic paraplegia.
    de Niet M; de Bot ST; van de Warrenburg BP; Weerdesteyn V; Geurts AC
    J Rehabil Med; 2015 Feb; 47(2):147-53. PubMed ID: 25325386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia - The SPASTOX Trial.
    Diniz de Lima F; Faber I; Servelhere KR; Bittar MFR; Martinez ARM; Piovesana LG; Martins MP; Martins CR; Benaglia T; de Sá Carvalho B; Nucci A; França MC
    Mov Disord; 2021 Jul; 36(7):1654-1663. PubMed ID: 33595142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobile digital gait analysis captures effects of botulinum toxin in hereditary spastic paraplegia.
    Ibrahim AA; Ollenschläger M; Klebe S; Schüle R; Jeschonneck N; Kellner M; Loris E; Greinwalder T; Eskofier BM; Winkler J; Gaßner H; Regensburger M
    Eur J Neurol; 2024 Aug; 31(8):e16367. PubMed ID: 38859620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of gait parameters to predict the effectiveness of botulinum toxin injection in the spastic rectus femoris muscle of stroke patients with stiff knee gait.
    Roche N; Boudarham J; Hardy A; Bonnyaud C; Bensmail B
    Eur J Phys Rehabil Med; 2015 Aug; 51(4):361-70. PubMed ID: 25213306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia--report of 19 cases.
    Hecht MJ; Stolze H; Auf dem Brinke M; Giess R; Treig T; Winterholler M; Wissel J;
    Mov Disord; 2008 Jan; 23(2):228-33. PubMed ID: 17999430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in Patients with Strumpell-Lorrain Disease.
    Riccardo M; Angela L; Angela D; Vita P; Giulio L; Pietroq F; Giancarlo I; Marisa M
    Curr Pharm Des; 2016; 22(6):758-63. PubMed ID: 26648460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin injections for pediatric patients with hereditary spastic paraparesis.
    Geva-Dayan K; Domenievitz D; Zahalka R; Fattal-Valevski A
    J Child Neurol; 2010 Aug; 25(8):969-75. PubMed ID: 20406997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of botulinum toxin type A for spastic foot in post-stroke patients enrolled in a rehabilitation program.
    Pimentel LH; Alencar FJ; Rodrigues LR; Sousa FC; Teles JB
    Arq Neuropsiquiatr; 2014 Jan; 72(1):28-32. PubMed ID: 24637979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of botulinum toxin for spasticity after spinal cord injury.
    Marciniak C; Rader L; Gagnon C
    Am J Phys Med Rehabil; 2008 Apr; 87(4):312-7; quiz 318-20, 329. PubMed ID: 18356622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional effects of botulinum toxin type A in the hip adductors and subsequent stretching in patients with hereditary spastic paraplegia.
    van Lith BJH; den Boer J; van de Warrenburg BPC; Weerdesteyn V; Geurts AC
    J Rehabil Med; 2019 Jun; 51(6):434-441. PubMed ID: 30968942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot.
    Mancini F; Sandrini G; Moglia A; Nappi G; Pacchetti C
    Neurol Sci; 2005 Apr; 26(1):26-31. PubMed ID: 15877184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum Toxin Type A and Physiotherapy in Spasticity of the Lower Limbs Due to Amyotrophic Lateral Sclerosis.
    Marvulli R; Megna M; Citraro A; Vacca E; Napolitano M; Gallo G; Fiore P; Ianieri G
    Toxins (Basel); 2019 Jul; 11(7):. PubMed ID: 31266172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin-A with and without rehabilitation for the treatment of spastic cerebral palsy.
    Jianjun L; Shurong J; Weihong W; Yan Z; Fanyong Z; Nanling L
    J Int Med Res; 2013 Jun; 41(3):636-41. PubMed ID: 23696596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure.
    Mall V; Heinen F; Kirschner J; Linder M; Stein S; Michaelis U; Bernius P; Lane M; Korinthenberg R
    J Child Neurol; 2000 Apr; 15(4):214-7. PubMed ID: 10805185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin type A for refractory post-stroke shoulder pain.
    Pedreira G; Cardoso E; Melo A
    Arq Neuropsiquiatr; 2008 Jun; 66(2A):213-5. PubMed ID: 18545785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity.
    Yang TF; Fu CP; Kao NT; Chan RC; Chen SJ
    Am J Phys Med Rehabil; 2003 Apr; 82(4):284-9. PubMed ID: 12649654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A French observational study of botulinum toxin use in the management of children with cerebral palsy: BOTULOSCOPE.
    Chaléat-Valayer E; Parratte B; Colin C; Denis A; Oudin S; Bérard C; Bernard JC; Bourg V; Deleplanque B; Dulieu I; Evrard P; Filipetti P; Flurin V; Gallien P; Héron-Long B; Hodgkinson I; Husson I; Jaisson-Hot I; Maupas E; Meurin F; Monnier G; Pérennou D; Pialoux B; Quentin V; Moreau MS; Schneider M; Yelnik A; Marque P
    Eur J Paediatr Neurol; 2011 Sep; 15(5):439-48. PubMed ID: 21745754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with Botulinum toxin A in a total population of children with cerebral palsy - a retrospective cohort registry study.
    Franzén M; Hägglund G; Alriksson-Schmidt A
    BMC Musculoskelet Disord; 2017 Dec; 18(1):520. PubMed ID: 29228927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.